{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:19Z","timestamp":1793830459405,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07726-w","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:49:05Z","timestamp":1767433745000},"page":"3799-3808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"53","author":[{"given":"Emilia","family":"Zampella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Piscopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gaudieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Caiazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-7658","authenticated-orcid":false,"given":"Alberto","family":"Cuocolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Klain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"7726_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61\u201372.","journal-title":"Lancet Oncol"},{"key":"7726_CR2","doi-asserted-by":"crossref","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138.","DOI":"10.1111\/his.13975"},{"key":"7726_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"7726_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24:152\u201360.","journal-title":"Ann Oncol"},{"key":"7726_CR5","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/cncr.28721","volume":"120","author":"H Sorbye","year":"2014","unstructured":"Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120:2814\u201323.","journal-title":"Cancer"},{"key":"7726_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ecl.2018.05.001","volume":"47","author":"H Sorbye","year":"2018","unstructured":"Sorbye H, Baudin E, Perren A. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinol Metab Clin North Am. 2018;47:683\u201398.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"7726_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","volume":"39","author":"JR Strosberg","year":"2010","unstructured":"Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799\u2013800.","journal-title":"Pancreas"},{"key":"7726_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","volume":"103","author":"R Garcia-Carbonero","year":"2016","unstructured":"Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186\u201394.","journal-title":"Neuroendocrinology"},{"key":"7726_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360.","journal-title":"Ann Oncol"},{"key":"7726_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","volume":"440","author":"M Papotti","year":"2002","unstructured":"Papotti M, Bongiovanni M, Volante M, All\u00eca E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1\u20135 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461\u201375.","journal-title":"Virchows Arch"},{"key":"7726_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"7726_CR12","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363.","journal-title":"Lancet Oncol"},{"key":"7726_CR13","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.3390\/curroncol31090416","volume":"31","author":"L Piscopo","year":"2024","unstructured":"Piscopo L, Zampella E, Volpe F, Gaudieri V, Nappi C, Di Donna E, et al. The safety and efficacy of peptide receptor radionuclide therapy for gastro-entero-pancreatic neuroendocrine tumors: a single center experience. Curr Oncol. 2024;31:5617\u201329.","journal-title":"Curr Oncol"},{"key":"7726_CR14","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124\u201330.","journal-title":"J Clin Oncol"},{"key":"7726_CR15","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"7726_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1530\/ERC-18-0424","volume":"26","author":"EA Carlsen","year":"2019","unstructured":"Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26:227\u201339.","journal-title":"Endocr Relat Cancer"},{"key":"7726_CR17","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","volume":"50","author":"M Mitjavila","year":"2023","unstructured":"Mitjavila M, Jimenez-Fonseca P, Bell\u00f3 P, Pubul V, Percovich JC, Garcia-Burillo A, et al. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023;50:2486\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7726_CR18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00259-017-3925-8","volume":"45","author":"S Nicolini","year":"2018","unstructured":"Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, et al. Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging. 2018;45:923\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7726_CR19","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1159\/000525216","volume":"112","author":"N Raj","year":"2022","unstructured":"Raj N, Coffman K, Le T, Do RKG, Rafailov J, Choi Y, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to lutetium-177-DOTATATE. Neuroendocrinology. 2022;112:1177\u201386.","journal-title":"Neuroendocrinology"},{"key":"7726_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00259-017-3821-2","volume":"45","author":"SP Thang","year":"2018","unstructured":"Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018;45:262\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7726_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2967\/jnumed.118.215848","volume":"60","author":"J Zhang","year":"2019","unstructured":"Zhang J, Kulkarni HR, Singh A, Niepsch K, M\u00fcller D, Baum RP. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med. 2019;60:377\u201385.","journal-title":"J Nucl Med"},{"key":"7726_CR22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.2967\/jnumed.119.241414","volume":"61","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP. Prognostic value of 18F-FDG PET\/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy. J Nucl Med. 2020;61:1560\u20139.","journal-title":"J Nucl Med"},{"key":"7726_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaf J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"7726_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"7726_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13:147\u201353.","journal-title":"Int J Evid Based Healthc"},{"key":"7726_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"7726_CR27","unstructured":"Higgins JPT, Thomas J. Cochrane Handbook for Systematic Reviews of Interventions; version 6.5, 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current."},{"key":"7726_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/0272989X05282643","volume":"25","author":"AE Ades","year":"2005","unstructured":"Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25:646\u201354.","journal-title":"Med Decis Making"},{"key":"7726_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"7726_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56\u201373.","journal-title":"Eur J Cancer"},{"key":"7726_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000348394","volume":"97","author":"M Sansovini","year":"2013","unstructured":"Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, et al. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97:347\u201354.","journal-title":"Neuroendocrinology"},{"key":"7726_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00259-020-04873-0","volume":"48","author":"G Paganelli","year":"2021","unstructured":"Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, et al. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur J Nucl Med Mol Imaging. 2021;48:152\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7726_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","volume":"41","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7726_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081936","volume":"13","author":"L Apostolidis","year":"2021","unstructured":"Apostolidis L, Dal Buono A, Merola E, Jann H, J\u00e4ger D, Wiedenmann B, et al. Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3). Cancers (Basel). 2021;13:1936.","journal-title":"Cancers (Basel)"},{"key":"7726_CR35","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41416-023-02462-0","volume":"129","author":"S Morken","year":"2023","unstructured":"Morken S, Langer SW, Sundl\u00f6v A, Vestermark LW, Ladekarl M, Hjortland GO, et al. Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer. 2023;129:1930\u20139.","journal-title":"Br J Cancer"},{"key":"7726_CR36","first-page":"C31","volume":"108","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. First-line efficacy of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: phase 3 NETTER-2 subgroup analysis. Endocr Abstr. 2024;108:C31.","journal-title":"Endocr Abstr"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07726-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:36Z","timestamp":1777274796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07726-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7726"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07726-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any study with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Alberto Cuocolo declared the following conflict of interest: European Journal of Nuclear Medicine and Molecular Imaging, Associate Editor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}